Adaptimmune Therapeutics plc (ADR)

General ticker "ADAP" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $209.0M (TTM average)

Adaptimmune Therapeutics plc (ADR) does not follow the US Stock Market performance with the rate: -6.7%.

Estimated limits based on current volatility of 4.2%: low 0.27$, high 0.29$

Factors to consider:

  • Current price 50.5% below estimated low

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [0.56$, 1.78$]
  • 2025-12-31 to 2026-12-31 estimated range: [0.71$, 2.07$]

Financial Metrics affecting the ADAP estimates:

  • Negative: Non-GAAP EPS, $ of -0.27 <= 0.04
  • Negative: Operating cash flow per share per price, % of -31.24 <= 1.79
  • Negative: negative Operating income
  • Negative: negative Net income
  • Positive: Interest expense per share, $ of 0.01 <= 0.10
  • Negative: Shareholder equity ratio, % of 4.82 <= 22.52
  • Positive: -0.87 < Investing cash flow per share, $ of -0.23
  • Positive: Industry inventory ratio change (median), % of 0 <= 0

Similar symbols

Short-term ADAP quotes

2025-03-202025-03-212025-03-242025-03-252025-03-262025-03-272025-03-282025-03-312025-04-012025-04-022025-04-032025-04-042025-04-072025-04-082025-04-092025-04-102025-04-112025-04-142025-04-152025-04-162025-04-172025-04-212025-04-222025-04-232025-04-242025-04-252025-04-282025-04-292025-04-302025-05-010.20.250.30.350.4
Price $

Long-term ADAP plot with estimates

0.511.52Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025Jan 2026Jul 2026Jan 2027−0.200.2
ADAPS&P500Health CareNon-GAAP EPS EstimateNon-GAAP EPS ActualPrice $Non-GAAP EPS $

Financial data

YTD 2022-12-31 2023-12-31 2024-12-31
Operating Revenue $27.15MM $60.28MM $178.03MM
Operating Expenses $191.11MM $200.02MM $246.79MM
Operating Income $-163.97MM $-139.74MM $-68.76MM
Non-Operating Income $1.01MM $27.21MM $1.52MM
Interest Expense $0.00MM $0.00MM $3.35MM
R&D Expense $127.73MM $126.51MM $149.06MM
Income(Loss) $-162.96MM $-112.53MM $-67.24MM
Taxes $2.50MM $1.34MM $3.58MM
Profit(Loss)* $-165.46MM $-113.87MM $-70.81MM
Stockholders Equity $81.88MM $39.51MM $11.85MM
Inventory $1.28MM $0.00MM $7.32MM
Assets $328.92MM $282.62MM $245.96MM
Operating Cash Flow $-141.77MM $-140.88MM $-73.21MM
Capital expenditure $29.74MM $4.88MM $0.00MM
Investing Cash Flow $89.14MM $176.54MM $-58.95MM
Financing Cash Flow $12.87MM $0.88MM $78.75MM
Earnings Per Share** $-6.18 $-3.42 $-1.68
Ordinary share to ADR 0.17x 0.17x 0.17x

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.